# Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism

> **NCT02721888** · PHASE4 · TERMINATED · sponsor: **Centre Hospitalier Universitaire Dijon** · enrollment: 127 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
- **BIOLOGICAL:** Blood sample
- **OTHER:** Kinetic substudy (10 patients)

## Key facts

- **NCT ID:** NCT02721888
- **Lead sponsor:** Centre Hospitalier Universitaire Dijon
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07-10
- **Primary completion:** 2019-10-02
- **Final completion:** —
- **Target enrollment:** 127 (ACTUAL)
- **Why stopped:** Failure of inclusion
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02721888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02721888, "Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02721888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*